Three-year follow-up from the phase I/IIa trial of rAAV.sFlt-1 subretinal injection is encouraging for gene therapy for exudative age-related macular degeneration.
Michelle Dalton, ELS
Advertisement
Articles by Michelle Dalton, ELS
Advertisement
Latest Updated Articles
- Gene therapy for wet AMD shows promising long-term results
Published: February 1st 2016 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
FasTCAR Manufactured BCMAxCD19 CAR T-cell Therapy Shows Promise for Multiple Myeloma
2
Autologous Stem Cell Therapy for Alzheimer Disease Advances to Phase 2 After Positive Early Findings
3
FDA Approves BMS’s Liso-Cel for R/R Marginal Zone Lymphoma
4
ImmunoLogic, Episode 7: "Turbocharging CAR T-Cells: The IL-9 Orthogonal Signal" With Anusha Kalbasi, MD
5
